SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
8-K	Sep 21, 2026	Sep 21, 2026	View filing
4/A	Aug 28, 2026	Aug 28, 2026	View filing
4/A	Aug 28, 2026	Aug 28, 2026	View filing
SC 13D	Aug 21, 2026	Aug 21, 2026	View filing
EFFECT	Aug 20, 2026	Aug 21, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
4	Aug 17, 2026	Aug 17, 2026	View filing
4	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
S-3	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 3, 2026	Aug 3, 2026	View filing
4	Aug 3, 2026	Aug 3, 2026	View filing
3	Aug 3, 2026	Aug 3, 2026	View filing
4/A	Jul 30, 2026	Jul 30, 2026	View filing
D	Jul 22, 2026	Jul 22, 2026	View filing
4	Jul 15, 2026	Jul 15, 2026	View filing
3	Jul 15, 2026	Jul 15, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
8-K	Jul 10, 2026	Jul 10, 2026	View filing
EFFECT	Jul 1, 2026	Jul 2, 2026	View filing
S-3	Jun 18, 2026	Jun 18, 2026	View filing
EFFECT	Jun 17, 2026	Jun 18, 2026	View filing

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Boston, MA

29 employees

www.cuebiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shao-Lee Lin

View full financials